SLXN
Silexion Therapeutics Ltd.NASDAQHealthcare$1.15-4.96%ClosedMarket Cap: $645,109
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.38
P/S
0.00
EV/EBITDA
0.41
DCF Value
$3.59
FCF Yield
-1678.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-387.8%
ROA
-165.1%
ROIC
-250.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-4.4M | $-4.4M | $-1.41 | — |
| FY 2025 | $0.00 | -Infinity% | $-11.6M | $-11.9M | $-8.96 | — |
| Q3 2025 | $0.00 | -Infinity% | $-3.3M | $-3.3M | $2.88 | — |
| Q2 2025 | $0.00 | -Infinity% | $-2.3M | $-2.5M | $4.32 | — |
| Q1 2025 | $0.00 | NaN% | $-1.6M | $-1.7M | $-0.26 | — |
| Q4 2024 | $0.00 | NaN% | $-23.2K | $-31.1K | $-0.19 | — |
| FY 2024 | $0.00 | NaN% | $-12.6M | $-16.4M | $-2.64 | — |
| Q3 2024 | $0.00 | -Infinity% | $-8.0M | $-11.9M | $-1.15 | — |
| Q2 2024 | $0.00 | -Infinity% | $-1.4M | $-1.5M | $-0.03 | — |
| Q1 2024 | $0.00 | NaN% | $-1.3M | $-1.4M | $-1.27 | — |
| Q4 2023 | $0.00 | NaN% | $-1.7M | $-1.7M | $-1.78 | — |
| FY 2023 | $0.00 | NaN% | $-4.7M | $-4.9M | $-4.42 | — |